The hallucinogenic world of tryptamines: an updated review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical, historical, and clinical literature without systematic review methodology
PubMed 25877327 · doi:10.1007/s00204-015-1513-x
What was done
This paper reviewed the literature on classical (e.g., psilocybin, DMT) and synthetic designer tryptamines (e.g., AMT, 5-MeO-DMT, 5-MeO-DIPT). It summarized their historical background, prevalence, legal status, chemical properties, toxicokinetics, pharmacodynamics, and observed physiological and toxicological effects across animal and human data.
What was found
The abstract reports no quantitative metrics or statistical values. It qualitatively reports that tryptamines act primarily as 5-HT2A receptor agonists to alter perception, mood, and thought, and notes that newer synthetic variants marketed as research chemicals or legal alternatives have been associated with intoxication and fatal outcomes.
Why it matters
It consolidates existing knowledge on emerging synthetic tryptamine derivatives, helping toxicologists and clinicians recognize their mechanisms and associated health risks.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis. It does not provide quantitative effect estimates or study counts, and explicitly notes that the literature on the toxicology and pharmacology of novel synthetic tryptamines remains sparse.